Dexamethasone + Iberdomide Hydrochloride
Phase 2Recruiting 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Smoldering Plasma Cell Myeloma
Conditions
Smoldering Plasma Cell Myeloma
Trial Timeline
Nov 2, 2021 → Sep 1, 2029
NCT ID
NCT04776395About Dexamethasone + Iberdomide Hydrochloride
Dexamethasone + Iberdomide Hydrochloride is a phase 2 stage product being developed by Bristol Myers Squibb for Smoldering Plasma Cell Myeloma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04776395. Target conditions include Smoldering Plasma Cell Myeloma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04776395 | Phase 2 | Recruiting |
Competing Products
13 competing products in Smoldering Plasma Cell Myeloma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Elotuzumab (BMS-901608; HuLuc63) | AbbVie | Phase 2 | 52 |
| BHQ880 | Novartis | Phase 2 | 52 |
| carfilzomib + Lenalidomide + Dexamethasone + Melphalan | Amgen | Phase 2 | 51 |
| Denosumab | Amgen | Phase 2 | 51 |
| Carfilzomib + Lenalidomide + Daratumumab + Dexamethasone | Amgen | Phase 2 | 51 |
| Elranatamab | Pfizer | Phase 2 | 51 |
| Nivolumab + Lenalidomide + Dexamethasone | Bristol Myers Squibb | Phase 2 | 51 |
| Elotuzumab + Lenalidomide + Dexamethasone | Bristol Myers Squibb | Phase 2 | 51 |
| Linvoseltamab | Regeneron Pharmaceuticals | Phase 2 | 51 |
| Linvoseltamab + Daratumumab | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Selinexor | Karyopharm Therapeutics | Phase 2 | 44 |
| IPH2101 | Innate Pharma | Phase 2 | 44 |
| PD-L1 peptide | IO Biotech | Phase 2 | 44 |